A galactosemia clássica é uma doença metabólica com risco de vida, com início no período neonatal. Os bebês geralmente desenvolvem dificuldades de alimentação, letargia e doença hepática grave.
Introdução
O que você precisa saber de cara
A galactosemia clássica é uma doença metabólica com risco de vida, com início no período neonatal. Os bebês geralmente desenvolvem dificuldades de alimentação, letargia e doença hepática grave.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 33 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 77 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Triagem neonatal (Teste do Pezinho)
A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.
Plays an important role in galactose metabolism
Galactosemia 1
A form of galactosemia, an inborn error of galactose metabolism typically manifesting in the neonatal period, after ingestion of galactose, with jaundice, hepatosplenomegaly, hepatocellular insufficiency, food intolerance, hypoglycemia, renal tubular dysfunction, muscle hypotonia, sepsis and cataract. GALAC1 inheritance is autosomal recessive.
Variantes genéticas (ClinVar)
499 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
2 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Deficiência de galactose-1-fosfato uridiltransferase
Centros de Referência SUS
21 centros habilitados pelo SUS para Deficiência de galactose-1-fosfato uridiltransferase
Centros para Deficiência de galactose-1-fosfato uridiltransferase
Detalhes dos centros
Hospital Universitário Prof. Edgard Santos (HUPES)
R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808
Serviço de Referência
Hospital de Apoio de Brasília (HAB)
AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456
Serviço de Referência
Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)
Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207
Serviço de Referência
Hospital das Clínicas da UFG
Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424
Serviço de Referência
Hospital das Clínicas da UFMG
Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167
Serviço de Referência
NUPAD / Faculdade de Medicina UFMG
Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226
Serviço de Referência
Hospital Universitário João de Barros Barreto
R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878
Serviço de Referência
Hospital de Clínicas da Universidade Federal de Pernambuco
Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492
Atenção Especializada
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647
Serviço de Referência
Hospital de Clínicas da UFPR
R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980
Serviço de Referência
Hospital Universitário Pedro Ernesto (HUPE-UERJ)
Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221
Serviço de Referência
Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)
Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988
Serviço de Referência
Hospital Universitário Onofre Lopes (HUOL)
Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570
Atenção Especializada
Hospital São Lucas da PUCRS
Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928
Serviço de Referência
Hospital de Clínicas de Porto Alegre (HCPA)
Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601
Serviço de Referência
Hospital Universitário da UFSC (HU-UFSC)
R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356
Serviço de Referência
Hospital das Clínicas da FMUSP
R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485
Serviço de Referência
Hospital de Clínicas da UNICAMP
R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223
Serviço de Referência
Hospital de Clínicas de Ribeirão Preto (HCRP-USP)
R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187
Serviço de Referência
Instituto da Criança e do Adolescente (ICr-HCFMUSP)
Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695
Serviço de Referência
UNIFESP / Hospital São Paulo
R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689
Serviço de Referência
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
15 ensaios clínicos encontrados, 2 ativos.
Publicações mais relevantes
Coagulopathy in Neonates With Classic Galactosemia: A Life-Threatening Yet Underrecognized Complication.
Classic galactosemia (CG) is a rare metabolic disorder caused by galactose-1-phosphate uridylyltransferase deficiency, leading to toxic metabolite accumulation and life-threatening complications such as failure to thrive, sepsis, and acute liver failure. We hypothesize that coagulopathy is an underrecognized complication of CG and that this gap is reflected by limited documentation in the medical literature. A PubMed literature review was conducted to identify articles describing coagulopathy in CG. We filtered for guidelines, meta-analyses, reviews, and systematic reviews. Our article screening followed PRISMA guidelines. Of 49 identified articles, 26/49 (53%) met inclusion criteria. Only 6/49 (12%) explicitly described coagulopathy in CG, and only 1/49 (2%) discussed management. These data supports our hypothesis that coagulopathy may be an underrecognized complication of CG by clinicians and identifies a gap in current medical literature. Improved early recognition of coagulopathy in neonates with CG could prevent delays in treatment and improve outcomes.
Pretreatment With a Selected Strain of Baker's Yeast, GY007, Prevents the Accumulation of Galactose Metabolites Following Dietary Galactose Exposure in a GALT-Null Rat Model of Classic Galactosemia.
The current standard of care for patients with classic galactosemia (CG) involves lifelong dietary restriction of high galactose foods, including most dairy products. Here, we present the results of a pilot study testing whether pretreatment with GY007, a strain of baker's yeast selected to metabolize galactose despite the presence of other sugars, would be sufficient to prevent the metabolic impact of dietary galactose exposure in a GALT-null rat model of CG. Specifically, we dosed cohorts of adolescent GALT-null rats with either (a) placebo alone, (b) placebo followed by galactose, or (c) GY007 yeast followed by galactose. All rats were treated 3 times daily for 8 consecutive days, for a combined daily dose of almost 27 mg galactose per rat. Wild-type rats dosed with placebo served as controls. All rats also had ad libitum access to water and chow that contained about 0.15% calories from galactose. Rats grew at the expected pace for the duration of the study regardless of treatment group. To test the metabolic efficacy of the GY007 pretreatment, we followed galactose, galactitol, and gal-1P longitudinally in blood, and at euthanasia in brain and liver. In both liver and red blood cells, most metabolites remained near placebo levels despite the galactose exposure, limiting our ability to test the efficacy of GY007 pretreatment in those tissues. However, in both plasma and brain, metabolites showed a significant elevation following galactose exposure, and this rise was prevented by pretreatment with GY007. These results demonstrate the potential of GY007 yeast to prevent the metabolic consequences of transient low-level dietary galactose exposure in GALT deficiency.
Myo-Inositol Deficiency, Structural Brain Changes, and Cerebral Perfusion Alterations in Classic Galactosemia: Preliminary Insights From a Multiparametric MRI Study.
Classic galactosemia is a rare metabolic disorder resulting from galactose-1-phosphate uridylyltransferase deficiency, which disrupts normal galactose metabolism, leading to toxic accumulation of galactose-1-phosphate and galactitol. Despite early dietary intervention, patients remain at risk for long-term neurological impairments, including cognitive deficits, motor speech disorders, and psychiatric conditions. The mechanisms driving these persistent abnormalities remain unclear. This study investigated brain metabolic and structural alterations in adults with classic galactosemia using advanced multiparametric MRI. Six patients (3 males, 3 females; mean age 34.0 ± 7.3 years) adhering to lifelong galactose-restricted diets and six age- and sex-matched controls underwent 3T and 7T MRI, including T1-weighted imaging, pseudo-continuous arterial spin labeling, and high-resolution MR spectroscopic imaging. Patients exhibited significantly lower myo-inositol (mIns) concentrations in cerebellum (p = 0.007), putamen (p = 0.023), and cerebral white matter (p = 0.001), reflecting a chronic mIns deficiency despite dietary management. Structural analyses revealed reduced volumes of white matter (p < 0.001), bilateral putamen (p < 0.038), and left thalamus (p = 0.044); alongside increased cortical thickness and reduced cortical surface area, indicating abnormal cortical maturation, particularly in regions associated with motor and cognitive processing. Additionally, cerebral blood flow was elevated in emotion-processing regions, including bilateral amygdala (p < 0.022) and thalamus (p < 0.038). These preliminary findings highlight persistent neurological alterations in classic galactosemia despite dietary management and suggest that chronic mIns deficiency may contribute to the pathophysiology. They underscore the need for larger, longitudinal studies to confirm these results, investigate potential correlations with clinical severity and biochemical markers, and explore therapeutic strategies aimed at modulating mIns metabolism.
Exit interviews with caregivers of pediatric patients with classic galactosemia to explore meaningfulness of changes in the ACTION-galactosemia kids trial.
Classic Galactosemia is a rare, autosomal recessive disease in which galactose is not metabolized properly due to severe deficiency/absence of the galactose-1-phosphate uridylyltransferase (GALT) enzyme, converting to an aberrant and toxic metabolite, galactitol. Living with the debilitating symptoms and long-term consequences of Classic Galactosemia creates a heavy burden on patients' and their families' lives. Objectives were to: (1) Evaluate the impact and burden of disease; (2) Qualitatively explore changes in patient symptoms following treatment; and (3) Document the meaningfulness of changes resulting from treatment with govorestat as assessed by the Caregiver Global Impression of Severity (CGIS) and Caregiver Global Impression of Change (CGIC) scales. The AT-007-1002 clinical trial involved a Phase 1/2 dose escalation component (Part A) followed by a Phase 3, randomized, double-blind, placebo-controlled long-term administration component (Part B) that evaluated potential clinical benefit. Exit Interviews were completed prior to unblinding of data. The in-depth, qualitative interviews were semi-structured, using a discussion guide, and conducted by either Zoom or GoToMeeting. Thirty-six caregiver interviews were conducted, capturing the experience of 37 pediatric patients (one caregiver had 2 patients enrolled in the study). Thematic analysis was undertaken to identify themes or patterns within the data. All analyses were conducted on blinded data. Following finalization of the analysis and report findings, post-hoc analysis of the unblinded data was then conducted to explore the meaningfulness of patients experience by treatment arm. This study confirms the substantial burden known to be associated with Classic Galactosemia in a pediatric population. The difficulties experienced were across multiple areas including cognitive function, behavior/social function, motor function, emotional function, communication, vision problems, ovarian insufficiency, sensory difficulties, and sleep problems. The interviews demonstrated that most patients (approximately two thirds) experienced an improvement in symptoms and impacts associated with classic galactosemia over the course of the trial. Nearly all caregivers reported that they perceived a 1-category change on the Caregiver Global Impression of Severity or Caregiver Global Impression of Change items, indicating severity and change respectively, was meaningful to them and the patient. Unblinded analysis of the exit interview data confirmed the patient experience reported by caregivers was different between the treatment arms, providing qualitative support for the treatment benefit of govorestat when compared to placebo. Furthermore, the qualitative data from caregivers provide in-depth insights of their unique lived experience that highlight the substantial impact that this improvement had on the caregiver's and the patient's quality of life. The improvements observed led to a reduction on the burden of Classic Galactosemia and may lead to a greater patient's greater independence. The exit interviews confirmed the burden of Classic Galactosemia disease across multiple domains. Qualitative investigation suggests that observed changes are meaningful to the patient and caregiver, and changes were more commonly reported in those receiving govorestat compared to placebo. Full clinical trial findings will be published separately.
Patterns of Penetrance and Expressivity of Long-Term Outcomes in Classic Galactosemia.
Long-term complications are common among patients with classic galactosemia (CG) and show both reduced penetrance and variable expressivity. Overall prevalence rates for complications in cognitive, motor, and speech/voice/language outcomes among US and European cohorts are known. However, age at presentation, whether these complications cluster, and what factors might associate with penetrance remain unknown. These gaps in knowledge limit prognostic accuracy for young patients and leave open the question of whether complications in different outcome domains may have shared modifiers. Here we addressed these questions using data from medical records and family survey responses from 164 patients and 77 controls. We found that for cases who experienced long-term complications, the median age at presentation of challenges in cognitive outcome was about 5 years, in motor outcome was about 3 years, and in speech/voice/language outcome was about 2 years. We also found highly significant clustering of complications in these three domains. Finally, we tested six factors for possible association with penetrance: history of severe neonatal symptoms, GALT genotype and predicted residual GALT activity, days of neonatal milk exposure, rigor of non-dairy galactose restriction in early childhood, peak red blood cell (RBC) galactose-1P level in infancy, and baseline RBC galactose-1P level in early childhood. Of these, only history of severe neonatal brain-related symptoms consistently associated with higher penetrance, and only detectable predicted residual GALT activity consistently associated with lower penetrance. Combined, these results substantially extend what is known about the natural history of long-term complications in CG.
Publicações recentes
Heritability of Long-Term Complications in Classic Galactosemia.
Coagulopathy in Neonates With Classic Galactosemia: A Life-Threatening Yet Underrecognized Complication.
Experimental Galactose-1-Phosphate Uridylyltransferase (GALT) mRNA Therapy Improves Motor-Related Phenotypes in a Mouse Model of Classic Galactosemia-A Pilot Study.
Anxiety and stress in parents as well as the burden of raising a child with classical galactosemia.
📚 EuropePMC140 artigos no totalmostrando 150
Coagulopathy in Neonates With Classic Galactosemia: A Life-Threatening Yet Underrecognized Complication.
Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & PractitionersExperimental Galactose-1-Phosphate Uridylyltransferase (GALT) mRNA Therapy Improves Motor-Related Phenotypes in a Mouse Model of Classic Galactosemia-A Pilot Study.
BiomedicinesAnxiety and stress in parents as well as the burden of raising a child with classical galactosemia.
Psychiatria polskaPretreatment With a Selected Strain of Baker's Yeast, GY007, Prevents the Accumulation of Galactose Metabolites Following Dietary Galactose Exposure in a GALT-Null Rat Model of Classic Galactosemia.
Journal of inherited metabolic diseaseMyo-Inositol Deficiency, Structural Brain Changes, and Cerebral Perfusion Alterations in Classic Galactosemia: Preliminary Insights From a Multiparametric MRI Study.
Journal of inherited metabolic diseaseClassic galactosemia in the differential diagnosis of neonatal low gammaglutamyltransferase cholestasis.
Acta gastro-enterologica BelgicaExit interviews with caregivers of pediatric patients with classic galactosemia to explore meaningfulness of changes in the ACTION-galactosemia kids trial.
Orphanet journal of rare diseasesTranslating the Power of Precision Medicine Into the World of Communication Disorders.
Journal of speech, language, and hearing research : JSLHRSimultaneous, dual-target, bilateral deep brain stimulation for treatment of galactosemia-induced dystonia and tremor in a pediatric patient.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryA Pilot Study of Bone Marrow Transplantation in a GALT-Null Rat Model of Classic Galactosemia.
JIMD reportsClinical and genetic features of Classic Galactosemia in the south of Brazil.
Molecular genetics and metabolismPatterns of Penetrance and Expressivity of Long-Term Outcomes in Classic Galactosemia.
Journal of inherited metabolic diseaseUnusual Presentation of Classical Galactosemia: A Case Report of Iranian Experience.
Clinical case reportsReshaping the Treatment Landscape of a Galactose Metabolism Disorder.
Journal of inherited metabolic diseaseImprovement of Mutant Galactose-1-Phosphate Uridylyltransferase (GALT) Activity by FDA-Approved Pharmacochaperones: A Preliminary Study.
International journal of molecular sciencesHuman Milk Feeding in Inherited Metabolic Disorders: A Systematic Review of Growth, Metabolic Control, and Neurodevelopment Outcomes.
Journal of inherited metabolic diseaseAssessment of Long-Term Safety and Efficacy of Purple Sweet Potato Color (PSPC) and Myo-Inositol (MI) Treatment for Motor Related and Behavioral Phenotypes in a Mouse Model of Classic Galactosemia.
Journal of inherited metabolic diseasePrimary ovarian insufficiency in Classic Galactosemia: a systematic review.
Journal of endocrinological investigationResults of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia.
Journal of clinical pharmacologySingle-nucleus and spatial transcriptomics of paediatric ovary: Molecular insights into the dysregulated signalling pathways underlying premature ovarian insufficiency in classic galactosemia.
Clinical and translational medicineSocial cognition, psychosocial development and well-being in galactosemia.
Orphanet journal of rare diseasesMotor Milestones: Sensory Motor Trends of Young Children with Classic Galactosemia.
Journal of occupational therapy, schools & early interventionHealth and well-being of maturing adults with classic galactosemia.
Journal of inherited metabolic diseaseSafety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study.
Journal of clinical pharmacologyGalactose-1-phosphate inhibits cytochrome c oxidase and causes mitochondrial dysfunction in classic galactosemia.
Biochimica et biophysica acta. Molecular basis of diseaseGalactokinase 1 is the source of elevated galactose-1-phosphate and cerebrosides are modestly reduced in a mouse model of classic galactosemia.
JIMD reportsRestoring galactose metabolism without restoring GALT rescues both compromised survival in larvae and an adult climbing deficit in a GALT-null D. Melanogaster model of classic galactosemia.
Journal of inherited metabolic diseaseA case report of classic galactosemia with a GALT gene variant and a literature review.
BMC pediatricsOvarian histology in children with classic galactosemia and correlation with endocrine and metabolic markers.
Fertility and sterilityImpact of theta transcranial alternating current stimulation on language production in adult classic galactosemia patients.
Journal of inherited metabolic diseaseNatural history of three late-diagnosed classic Galactosemia patients.
Molecular genetics and metabolism reportsClinical and biochemical phenotypes, genotypes, and long-term outcomes of individuals with galactosemia type I from a single metabolic genetics center in Alberta.
Molecular genetics and metabolism reportsTwelve-year review of galactosemia newborn screening in Taiwan: Evolving methods and insights.
Molecular genetics and metabolism reportsUntreated Classic Galactosemia: A Rare Cause of Adult-Onset Progressive Cerebellar Ataxia - A Case Report.
Case reports in neurologyBrain function in classic galactosemia, a galactosemia network (GalNet) members review.
Frontiers in geneticsWhole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia.
Molecular therapy. Methods & clinical developmentSocial cognition, emotion regulation and social competence in classical galactosemia patients without intellectual disability.
Acta neuropsychiatricaClassic Galactosemia: Clinical and Computational Characterization of a Novel GALT Missense Variant (p.A303D) and a Literature Review.
International journal of molecular sciencesLong-term complications in classic galactosemia are not progressive.
Molecular genetics and metabolismGrip strength in patients with galactosemia and in a galactose-1-phosphate uridylyltransferase (GALT)-null rat model.
Journal of inherited metabolic diseaseUnderstanding the patient experience of Classic Galactosemia in pediatric and adult patients: increased disease burden, challenges with daily living, and how they evolve over time.
Journal of patient-reported outcomesClassical Hereditary galactosemia: findings in patients and animal models.
Metabolic brain diseaseNovel GALT variations and genetic spectrum in Turkish population with the correlation of genotype and phenotype.
Annals of human geneticsIn vitro galactose impairs energy metabolism in the brain of young rats: protective role of antioxidants.
Nucleosides, nucleotides & nucleic acidsVirtual Post-Intervention Speech and Language Assessment of Toddler and Preschool Participants in Babble Boot Camp.
Journal of speech, language, and hearing research : JSLHRSecondary Reporting of G6PD Deficiency on Newborn Screening.
International journal of neonatal screeningDesign and Outcomes of a Novel Multidisciplinary Ophthalmic Genetics Clinic.
GenesSuccessful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1-CDG).
JIMD reportsRacial and ethnic diversity of classic and clinical variant galactosemia in the United States.
Molecular genetics and metabolismComparison of In Vitro and In Silico Assessments of Human Galactose-1-Phosphate Uridylyltransferase Coding Variants.
CureusCo-Occurring Atypical Galactosemia and Wilson Disease.
Molecular syndromologyThe hypergonadotropic hypogonadism conundrum of classic galactosemia.
Human reproduction updateRare disease therapeutics: The future of medical genetics in a changing landscape.
Genetics in medicine : official journal of the American College of Medical GeneticsEarly postnatal alterations in follicular stress response and survival in a mouse model of Classic Galactosemia.
Journal of ovarian researchAll aspects of galactosemia: a single center experience.
Journal of pediatric endocrinology & metabolism : JPEMNeonatal classic galactosemia-diagnosis, clinical profile and molecular characteristics in unscreened Turkish population.
Journal of tropical pediatricsFeasibility of a Proactive Parent-Implemented Communication Intervention Delivered via Telepractice for Children With Classic Galactosemia.
American journal of speech-language pathologyLaparoscopic ovarian tissue harvesting for cryopreservation from a child with galactosemia.
Fertility and sterilityA multinational study of acute and long-term outcomes of Type 1 galactosemia patients who carry the S135L (c.404C > T) variant of GALT.
Journal of inherited metabolic diseaseHarnessing the Power of Purple Sweet Potato Color and Myo-Inositol to Treat Classic Galactosemia.
International journal of molecular sciencesPathophysiology of long-term complications in classic galactosemia: What we do and do not know.
Molecular genetics and metabolismTranslating principles of precision medicine into speech-language pathology: Clinical trial of a proactive speech and language intervention for infants with classic galactosemia.
HGG advancesNovel mRNA therapy restores GALT protein and enzyme activity in a zebrafish model of classic galactosemia.
Journal of inherited metabolic diseaseTransient Cytopenias as a Rare Presentation of Classic Galactosemia.
CureusQualitative interviews with adults with Classic Galactosemia and their caregivers: disease burden and challenges with daily living.
Orphanet journal of rare diseasesSphingolipid depletion suppresses UPR activation and promotes galactose hypersensitivity in yeast models of classic galactosemia.
Biochimica et biophysica acta. Molecular basis of diseasePathophysiology and management of classic galactosemic primary ovarian insufficiency.
Reproduction & fertilityNeonatal GALT gene replacement offers metabolic and phenotypic correction through early adulthood in a rat model of classic galactosemia.
Journal of inherited metabolic diseaseAAV-mediated expression of galactose-1-phosphate uridyltransferase corrects defects of galactose metabolism in classic galactosemia patient fibroblasts.
Journal of inherited metabolic diseaseTwo consecutive pregnancies in a patient with premature ovarian insufficiency in the course of classic galactosemia and a review of the literature.
Gynecological endocrinology : the official journal of the International Society of Gynecological EndocrinologyToward Preventing Speech and Language Disorders of Known Genetic Origin: First Post-Intervention Results of Babble Boot Camp in Children With Classic Galactosemia.
American journal of speech-language pathologySimulation of the Interactions of Arginine with Wild-Type GALT Enzyme and the Classic Galactosemia-Related Mutant p.Q188R by a Computational Approach.
Molecules (Basel, Switzerland)Analysis of the Structure-Function-Dynamics Relationships of GALT Enzyme and of Its Pathogenic Mutant p.Q188R: A Molecular Dynamics Simulation Study in Different Experimental Conditions.
Molecules (Basel, Switzerland)Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.
Journal of medicinal chemistryTransient developmental delays in infants with Duarte-2 variant galactosemia.
Molecular genetics and metabolismAssessment of galactose-1-phosphate uridyltransferase activity in cells and tissues.
Journal of biological methodsThe genetic basis of classical galactosaemia in Polish patients.
Orphanet journal of rare diseasesFragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia.
ACS chemical biologyHand fine motor control in classic galactosemia.
Journal of inherited metabolic diseaseVirus-Based Nanoreactors with GALT Activity for Classic Galactosemia Therapy.
ChemMedChemCurrent and Future Treatments for Classic Galactosemia.
Journal of personalized medicineA Case of UDP-Galactose 4'-Epimerase Deficiency Associated with Dyshematopoiesis and Atrioventricular Valve Malformations: An Exceptional Clinical Phenotype Explained by Altered N-Glycosylation with Relative Preservation of the Leloir Pathway.
Molecular syndromologyPuberty and fertility in classic galactosemia.
Endocrine connectionsA case of classic galactosemia manifesting as neonatal early and profound indirect hyperbilirubinemia.
Turk pediatri arsiviHigh-Throughput Sequencing Reveals the Loss-of-Function Mutations in GALT Cause Recessive Classical Galactosemia.
Frontiers in pediatricsA pilot study of neonatal GALT gene replacement using AAV9 dramatically lowers galactose metabolites in blood, liver, and brain and minimizes cataracts in GALT-null rat pups.
Journal of inherited metabolic diseaseIdentification of neuronal structures and pathways corresponding to clinical functioning in galactosemia.
Journal of inherited metabolic diseaseHow a baby with classic galactosemia was nearly missed: When the test succeeds but system fails.
American journal of medical genetics. Part AFluorinated Galactoses Inhibit Galactose-1-Phosphate Uridyltransferase and Metabolically Induce Galactosemia-like Phenotypes in HEK-293 Cells.
CellsThe yeast protein Ubx4p contributes to mitochondrial respiration and lithium-galactose-mediated activation of the unfolded protein response.
The Journal of biological chemistryA galactose-1-phosphate uridylyltransferase-null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue-specific and longitudinal differences in galactose metabolism.
Journal of inherited metabolic diseaseTransferrin isoelectric focusing for the investigation of congenital disorders of glycosylation: analysis of a ten-year experience in a Brazilian center.
Jornal de pediatriaRedox Proteomes in Human Physiology and Disease Mechanisms.
Journal of proteome researchCognitive functioning in patients with classical galactosemia: a systematic review.
Orphanet journal of rare diseasesNovel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia.
Molecular therapy : the journal of the American Society of Gene TherapyElevated urine oxalate and renal calculi in a classic galactosemia patient on soy-based formula.
JIMD reportsDehydroepiandrosterone supplementation attenuates ovarian ageing in a galactose-induced primary ovarian insufficiency rat model.
Journal of assisted reproduction and geneticsFunctional analysis of GALT variants found in classic galactosemia patients using a novel cell-free translation method.
JIMD reportsSalubrinal enhances eIF2α phosphorylation and improves fertility in a mouse model of Classic Galactosemia.
Biochimica et biophysica acta. Molecular basis of diseaseScreening for galactosemia: is there a place for it?
International journal of general medicineTongue Strength in Children With and Without Speech Sound Disorders.
American journal of speech-language pathologyThe natural history of classic galactosemia: lessons from the GalNet registry.
Orphanet journal of rare diseasesNovel Mutation in GALT Gene in Galactosemia Patient with Group B Streptococcus Meningitis and Acute Liver Failure.
Medicina (Kaunas, Lithuania)Toward a paradigm shift from deficit-based to proactive speech and language treatment: Randomized pilot trial of the Babble Boot Camp in infants with classic galactosemia.
F1000ResearchDiscovery of novel inhibitors of human galactokinase by virtual screening.
Journal of computer-aided molecular designThe ability of an LC-MS/MS-based erythrocyte GALT enzyme assay to predict the phenotype in subjects with GALT deficiency.
Molecular genetics and metabolismMetabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms.
European journal of pediatricsMetabolic perturbations in classic galactosemia beyond the Leloir pathway: Insights from an untargeted metabolomic study.
Journal of inherited metabolic diseaseArginine does not rescue p.Q188R mutation deleterious effect in classic galactosemia.
Orphanet journal of rare diseasesEffect of genotype on galactose-1-phosphate in classic galactosemia patients.
Molecular genetics and metabolismGalactose-1-Phosphate Uridyltransferase Activities in Different Genotypes: A Retrospective Analysis of 927 Samples.
The journal of applied laboratory medicinePilot study of classic galactosemia: Neurodevelopmental impact and other complications urge neonatal screening in Egypt.
Journal of advanced researchPresentation, progression, and predictors of ovarian insufficiency in classic galactosemia.
Journal of inherited metabolic diseaseIntrafamilial oocyte donation in classic galactosemia: ethical and societal aspects.
Journal of inherited metabolic diseaseBiochemical changes and clinical outcomes in 34 patients with classic galactosemia.
Journal of inherited metabolic diseaseFolate deficiency in patients with classical galactosemia: A novel finding that needs to be considered for dietary treatments.
The Turkish journal of pediatricsLaboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical GeneticsMolecular basis and clinical presentation of classic galactosemia in a Croatian population.
Journal of pediatric endocrinology & metabolism : JPEMPrimary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.
Journal of assisted reproduction and geneticsImpaired fertility and motor function in a zebrafish model for classic galactosemia.
Journal of inherited metabolic diseaseReversal of aberrant PI3K/Akt signaling by Salubrinal in a GalT-deficient mouse model.
Biochimica et biophysica acta. Molecular basis of diseaseExploration of the Brain in Rest: Resting-State Functional MRI Abnormalities in Patients with Classic Galactosemia.
Scientific reportsRigor of non-dairy galactose restriction in early childhood, measured by retrospective survey, does not associate with severity of five long-term outcomes quantified in 231 children and adults with classic galactosemia.
Journal of inherited metabolic diseaseFertility in adult women with classic galactosemia and primary ovarian insufficiency.
Fertility and sterilityClassic Galactosemia: Study on the Late Prenatal Development of GALT Specific Activity in a Sheep Model.
Anatomical record (Hoboken, N.J. : 2007)A novel splicing mutation in GALT gene causing Galactosemia in Ecuadorian family.
Clinica chimica acta; international journal of clinical chemistryGalactose and its Metabolites Deteriorate Metaphase II Mouse Oocyte Quality and Subsequent Embryo Development by Disrupting the Spindle Structure.
Scientific reportsSweet and sour: an update on classic galactosemia.
Journal of inherited metabolic diseaseThe galactose-induced decrease in phosphate levels leads to toxicity in yeast models of galactosemia.
Biochimica et biophysica acta. Molecular basis of diseaseClinical, molecular, and genetic evaluation of galactosemia in Turkish children.
Turk pediatri arsiviDrosophila melanogaster Models of Galactosemia.
Current topics in developmental biologyBone Health in Classic Galactosemia: Systematic Review and Meta-Analysis.
JIMD reportsMolecular basis of classic galactosemia from the structure of human galactose 1-phosphate uridylyltransferase.
Human molecular geneticsAssessment of ataxia phenotype in a new mouse model of galactose-1 phosphate uridylyltransferase (GALT) deficiency.
Journal of inherited metabolic diseaseAcute and long-term outcomes in a Drosophila melanogaster model of classic galactosemia occur independently of galactose-1-phosphate accumulation.
Disease models & mechanismsGrey matter density decreases as well as increases in patients with classic galactosemia: A voxel-based morphometry study.
Brain researchGastrointestinal Health in Classic Galactosemia.
JIMD reportsVariants of uncertain significance in newborn screening disorders: implications for large-scale genomic sequencing.
Genetics in medicine : official journal of the American College of Medical GeneticsClassic Galactosemia: Indian Scenario.
Indian pediatricsTeaching NeuroImages: Galactitol peak and fatal cerebral edema in classic galactosemia: Too much sugar in the brain.
NeurologyAffected functional networks associated with sentence production in classic galactosemia.
Brain researchGenetic and functional studies reveal a novel noncoding variant in GALT associated with a false positive newborn screening result for galactosemia.
Clinica chimica acta; international journal of clinical chemistryArginine Functionally Improves Clinically Relevant Human Galactose-1-Phosphate Uridylyltransferase (GALT) Variants Expressed in a Prokaryotic Model.
JIMD reportsNewborn screening for galactosemia: a 30-year single center experience.
World journal of pediatrics : WJPDevelopmental Outcomes of School-Age Children with Duarte Galactosemia: A Pilot Study.
JIMD reportsA De Novo Variant in Galactose-1-P Uridylyltransferase (GALT) Leading to Classic Galactosemia.
JIMD reportsRapid screening of classic galactosemia patients: a proof-of-concept study using high-throughput FTIR analysis of plasma.
The AnalystFunctional and structural impact of the most prevalent missense mutations in classic galactosemia.
Molecular genetics & genomic medicineClinical and molecular spectra in galactosemic patients from neonatal screening in northeastern Italy: structural and functional characterization of new variations in the galactose-1-phosphate uridyltransferase (GALT) gene.
GeneStructure activity relationships of human galactokinase inhibitors.
Bioorganic & medicinal chemistry lettersAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Deficiência de galactose-1-fosfato uridiltransferase.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Deficiência de galactose-1-fosfato uridiltransferase
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Coagulopathy in Neonates With Classic Galactosemia: A Life-Threatening Yet Underrecognized Complication.Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners· 2026· PMID 41746225mais citado
- Pretreatment With a Selected Strain of Baker's Yeast, GY007, Prevents the Accumulation of Galactose Metabolites Following Dietary Galactose Exposure in a GALT-Null Rat Model of Classic Galactosemia.
- Myo-Inositol Deficiency, Structural Brain Changes, and Cerebral Perfusion Alterations in Classic Galactosemia: Preliminary Insights From a Multiparametric MRI Study.
- Exit interviews with caregivers of pediatric patients with classic galactosemia to explore meaningfulness of changes in the ACTION-galactosemia kids trial.
- Patterns of Penetrance and Expressivity of Long-Term Outcomes in Classic Galactosemia.
- Heritability of Long-Term Complications in Classic Galactosemia.
- Experimental Galactose-1-Phosphate Uridylyltransferase (GALT) mRNA Therapy Improves Motor-Related Phenotypes in a Mouse Model of Classic Galactosemia-A Pilot Study.
- Anxiety and stress in parents as well as the burden of raising a child with classical galactosemia.
- Duarte Galactosemia.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:79239(Orphanet)
- OMIM OMIM:230400(OMIM)
- MONDO:0009258(MONDO)
- GARD:13639(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q5517832(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
